Riskpilot← Back to searchSign inGet full accessAureum Pharma AB
ABActiveOrg 5568103807Arenavägen 41 Plan 12Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20100 employees
Revenue 2024
SEK 1,4M
+2% vs 2023
EBITDA margin
32.2%
-51% vs 2023
Equity ratio
20.3%
Financial strength
Net profit 2024
SEK -10K
-256% vs 2023
| Revenue | SEK 1,4M | +2% |
| EBITDA | SEK 440K | -51% |
| Net profit | SEK -10K | -256% |
| Total assets | SEK 300K | -18% |
| Equity | SEK 61K | -14% |
| Employees | 0 | — |
Legal name
Aureum Pharma AB
Org number
5568103807
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 juni 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Styrelsen ska bestå av 1 styrelseledamot och 1 styrelsesuppleant.
Company purpose
Bolaget ska bedriva partihandel, import, lager och distribution samt tillverkning av och med humanläkemedel och veterinära läkemedel, växtbaserade extrakt, växtbaserade läkemedel och preparat, traditionella växtbaserade läkemedel. Forskning, utveckling och analys, om och av humanläkemedel, veterinära läkemedel, aktiva substanser och beredningar för läkemedel samt därmed förenlig verksamhet.
Address
Arenavägen 41 Plan 12
Email
angelica.ornell@aureumlife.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 468 | 648 | 1 342 | 1 368 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −469 | 216 | 519 | 894 | 440 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −469 | 216 | 519 | 894 | 440 |
| Net financials | — | — | −0 | −2 | −0 |
| Profit before tax | −469 | 216 | −232 | 7 | −10 |
| Tax | −0 | — | — | — | — |
| Net profit | −469 | 216 | −232 | 7 | −10 |
| Item | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 363 | 442 | 231 | 366 | 300 |
| Equity | 81 | 296 | 65 | 71 | 61 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 282 | 146 | 166 | 295 | 240 |
| Total debt | 282 | 146 | 166 | 295 | 240 |
EBITDA margin
32.2%
This company
15.8%
Market median
+104% vs market
20212024
Equity ratio
20.3%
This company
38.2%
Market median
-47% vs market
20212024
Return on equity
-16.7%
This company
18.4%
Market median
-191% vs market
20212024
Net profit margin
-0.7%
This company
8.1%
Market median
-109% vs market
20212024
Asset turnover
4.55×
This company
1.12×
Market median
+306% vs market
20212024
Debt / equity
3.93×
This company
0.62×
Market median
-534% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-07-01 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KR Chief Auditor | Chief Auditor | 2024 |
| Former (1) | ||
ST Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (5) | ||
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2020 | |
| Board of Directors | 2022 – 2026 | |
| Board of Directors | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Aureum Life investments AB
Aureum Pharma AB Board members of Aureum Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kent Robert Axgart Wennerlund | Chief Auditor | 0 companies |
| Sara Therese Frida Nader | Chief Executive Officer | 0 companies |
| Lina Johanna Körnemark | Deputy Board Member | 0 companies |
| Robert Edward Gunnar A Körnemark | Board of Directors | 0 companies |
| Erik Atakan Bertil Befrits | Deputy Board Member | 0 companies |
| Warisa Emretzon | Deputy Board Member | 0 companies |
| Angelica Maria Örnell | Board of Directors | 0 companies |
| Håkan Emretzon | Board of Directors | 0 companies |